Asier SÃjez-CiriÃ³n

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8333208/publications.pdf Version: 2024-02-01



ACIED SA:EZ-CIDIA3N

#	Article	IF	CITATIONS
1	Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control. Journal of Clinical Investigation, 2022, 132, .	8.2	15
2	Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers. Nature Communications, 2022, 13, 1944.	12.8	9
3	Novel role of UHRF1 in the epigenetic repression of the latent HIV-1. EBioMedicine, 2022, 79, 103985.	6.1	10
4	NK cell spatial dynamics and IgA responses in gut-associated lymphoid tissues during SIV infections. Communications Biology, 2022, 5, .	4.4	1
5	Immunometabolism and HIV-1 pathogenesis: food for thought. Nature Reviews Immunology, 2021, 21, 5-19.	22.7	55
6	The Genome-wide Methylation Profile of CD4+ T Cells From Individuals With Human Immunodeficiency Virus (HIV) Identifies Distinct Patterns Associated With Disease Progression. Clinical Infectious Diseases, 2021, 72, e256-e264.	5.8	13
7	Initiating Antiretroviral Treatment Early in Infancy Has Long-term Benefits on the Human Immunodeficiency Virus Reservoir in Late Childhood and Adolescence. Clinical Infectious Diseases, 2021, 73, e4214-e4222.	5.8	4
8	SIV-induced terminally differentiated adaptive NK cells in lymph nodes associated with enhanced MHC-E restricted activity. Nature Communications, 2021, 12, 1282.	12.8	24
9	Role of NKG2a/c+CD8+ TÂcells in pathogenic versus non-pathogenic SIV infections. IScience, 2021, 24, 102314.	4.1	8
10	CD32+CD4+ T Cells Sharing B Cell Properties Increase With Simian Immunodeficiency Virus Replication in Lymphoid Tissues. Frontiers in Immunology, 2021, 12, 695148.	4.8	8
11	Ultrasensitive Detection of p24 in Plasma Samples from People with Primary and Chronic HIV-1 Infection. Journal of Virology, 2021, 95, e0001621.	3.4	9
12	Antiretroviral therapy for HIV controllers: Reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort. EClinicalMedicine, 2021, 37, 100963.	7.1	5
13	Extremely low viral reservoir in treated chronically HIV-1-infected individuals. EBioMedicine, 2020, 57, 102830.	6.1	18
14	Optimal Maturation of the SIV-Specific CD8+ T Cell Response after Primary Infection Is Associated with Natural Control of SIV: ANRS SIC Study. Cell Reports, 2020, 32, 108174.	6.4	12
15	Affinity for the Interface Underpins Potency of Antibodies Operating In Membrane Environments. Cell Reports, 2020, 32, 108037.	6.4	10
16	Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1. Science Translational Medicine, 2020, 12, .	12.4	17
17	Antiapoptotic Clone 11-Derived Peptides Induce <i>In Vitro</i> Death of CD4 ⁺ T Cells Susceptible to HIV-1 Infection. Journal of Virology, 2020, 94, .	3.4	3
18	SUGT1 controls susceptibility to HIV-1 infection by stabilizing microtubule plus-ends. Cell Death and Differentiation, 2020, 27, 3243-3257.	11.2	10

Asier SÃiez-CiriÃ³N

#	Article	IF	CITATIONS
19	Metabolic plasticity of HIV-specific CD8+ T cells is associated with enhanced antiviral potential and natural control of HIV-1 infection. Nature Metabolism, 2019, 1, 704-716.	11.9	72
20	HIV controllers: to treat or not to treat? Is that the right question?. Lancet HIV,the, 2019, 6, e878-e884.	4.7	13
21	HIV-1 Envelope Overcomes NLRP3-Mediated Inhibition of F-Actin Polymerization for Viral Entry. Cell Reports, 2019, 28, 3381-3394.e7.	6.4	28
22	The Yellow Brick Road towards HIV Eradication. Trends in Immunology, 2019, 40, 465-467.	6.8	4
23	HIV Controllers Have Low Inflammation Associated with a Strong HIV-Specific Immune Response in Blood. Journal of Virology, 2019, 93, .	3.4	24
24	Safety of CD34+ Hematopoietic Stem Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46 in HIV-1 Infected Patients with High-Risk Lymphoma. Molecular Therapy - Methods and Clinical Development, 2019, 13, 303-309.	4.1	13
25	The proportion of CD57+ cells among effector CD8+ T cells is lower in HIV controllers compared with antiretroviral therapy-treated patients. Aids, 2019, 33, 2137-2147.	2.2	1
26	Cellular Metabolism Is a Major Determinant of HIV-1 Reservoir Seeding in CD4+ T Cells and Offers an Opportunity to Tackle Infection. Cell Metabolism, 2019, 29, 611-626.e5.	16.2	124
27	Dynamics in HIVâ€DNA levels over time in HIV controllers. Journal of the International AIDS Society, 2019, 22, e25221.	3.0	21
28	Immune Responses to Retroviruses. Annual Review of Immunology, 2018, 36, 193-220.	21.8	36
29	Cellular Determinants of HIV Persistence on Antiretroviral Therapy. Advances in Experimental Medicine and Biology, 2018, 1075, 213-239.	1.6	5
30	Post-treatment Controllers. , 2018, , 1655-1659.		1
31	Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents. Journal of Virology, 2017, 91, .	3.4	64
32	A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level. Open Forum Infectious Diseases, 2017, 4, ofx064.	0.9	45
33	Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. Journal of the International AIDS Society, 2017, 20, 21579.	3.0	107
34	HLA-B*14:02-Restricted Env-Specific CD8 + T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection. Journal of Virology, 2017, 91, .	3.4	14
35	p21 Restricts HIV-1 in Monocyte-Derived Dendritic Cells through the Reduction of Deoxynucleoside Triphosphate Biosynthesis and Regulation of SAMHD1 Antiviral Activity. Journal of Virology, 2017, 91, .	3.4	27
36	Strong ifitm1 Expression in CD4 T Cells in HIV Controllers Is Correlated With Immune Activation. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, e56-e59.	2.1	7

#	Article	IF	CITATIONS
37	Saporin-conjugated tetramers identify efficacious anti-HIV CD8+ T-cell specificities. PLoS ONE, 2017, 12, e0184496.	2.5	2
38	Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset. PLoS Pathogens, 2016, 12, e1005774.	4.7	50
39	International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine, 2016, 22, 839-850.	30.7	395
40	Preservation of Lymphopoietic Potential and Virus Suppressive Capacity by CD8+ T Cells in HIV-2–Infected Controllers. Journal of Immunology, 2016, 197, 2787-2795.	0.8	19
41	Polyfunctional HIV-specific T cells in Post-Treatment Controllers. Aids, 2016, 30, 2299-2302.	2.2	26
42	Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation. Journal of Virology, 2016, 90, 6148-6158.	3.4	50
43	HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV,the, 2016, 3, e49-e54.	4.7	131
44	Dendritic Cells from HIV Controllers Have Low Susceptibility to HIV-1 Infection In Vitro but High Capacity to Capture HIV-1 Particles. PLoS ONE, 2016, 11, e0160251.	2.5	18
45	Immediate T-Helper 17 Polarization Upon Triggering CD11b/c on HIV-Exposed Dendritic Cells. Journal of Infectious Diseases, 2015, 212, 44-56.	4.0	22
46	Long-Term Control of Simian Immunodeficiency Virus (SIV) in Cynomolgus Macaques Not Associated with Efficient SIV-Specific CD8 ⁺ T-Cell Responses. Journal of Virology, 2015, 89, 3542-3556.	3.4	21
47	Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. Journal of Antimicrobial Chemotherapy, 2015, 70, 2108-2120.	3.0	92
48	Posttreatment controllers. Current Opinion in HIV and AIDS, 2015, 10, 29-34.	3.8	24
49	Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips―and Immune Activation in the ANRS CO21 CODEX Study. PLoS ONE, 2015, 10, e0131922.	2.5	50
50	Blunted Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International HIV Controller Collaboration. PLoS ONE, 2014, 9, e85516.	2.5	34
51	Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130436.	4.0	24
52	The link between CD8+ T-cell antigen-sensitivity and HIV-suppressive capacity depends on HLA restriction, target epitope and viral isolate. Aids, 2014, 28, 477-486.	2.2	10
53	Both HLA-B*57 and Plasma HIV RNA Levels Contribute to the HIV-Specific CD8 ⁺ T Cell Response in HIV Controllers. Journal of Virology, 2014, 88, 176-187.	3.4	39
54	HIV cure research: Advances and prospects. Virology, 2014, 454-455, 340-352.	2.4	103

#	Article	IF	CITATIONS
55	Reply to Pauls et al.: p21 is a master regulator of HIV replication in macrophages through dNTP synthesis block. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1325-6.	7.1	15
56	High Eomesodermin Expression among CD57 ⁺ CD8 ⁺ T Cells Identifies a CD8 ⁺ T Cell Subset Associated with Viral Control during Chronic Human Immunodeficiency Virus Infection. Journal of Virology, 2014, 88, 11861-11871.	3.4	24
57	What is the significance of posttreatment control of HIV infection vis-Ã-vis functional cure?. Aids, 2014, 28, 603-605.	2.2	5
58	Elevated IP10 levels are associated with immune activation and low CD4+ T-cell counts in HIV controller patients. Aids, 2014, 28, 467-476.	2.2	85
59	Potential Role for HIV-Specific CD38â^'/HLA-DR+ CD8+ T Cells in Viral Suppression and Cytotoxicity in HIV Controllers. PLoS ONE, 2014, 9, e101920.	2.5	90
60	Post-treatment Controllers. , 2014, , 1-6.		0
61	<scp>HIV</scp> controllers: a genetically determined or inducible phenotype?. Immunological Reviews, 2013, 254, 281-294.	6.0	57
62	RNR2 repression by p21 restricts reverse transcription of HIV-1 and related-lentiviruses in macrophages. Retrovirology, 2013, 10, .	2.0	0
63	Immunodominance of HLA-B27-restricted HIV KK10-specific CD8+ T-cells is not related to naÃ⁻ve precursor frequency. Immunology Letters, 2013, 149, 119-122.	2.5	11
64	Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. PLoS Pathogens, 2013, 9, e1003211.	4.7	879
65	p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E3997-4006.	7.1	83
66	Immunovirologic Control 24 Months After Interruption of Antiretroviral Therapy Initiated Close to HIV Seroconversion. JAMA Internal Medicine, 2013, 173, 475.	5.1	12
67	Will it be possible to live without antiretroviral therapy?. Current Opinion in HIV and AIDS, 2013, 8, 196-203.	3.8	5
68	NKG2D Expression on HIV-Specific CD8+ T cells Is Reduced in Viremic HIV-1–Infected Patients but Maintained in HIV Controllers. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 17-20.	2.1	5
69	CD8 T-Cells from Most HIV-Infected Patients Lack Ex Vivo HIV-Suppressive Capacity during Acute and Early Infection. PLoS ONE, 2013, 8, e59767.	2.5	21
70	High Antibody-Dependent Cellular Cytotoxicity Responses Are Correlated with Strong CD8 T Cell Viral Suppressive Activity but Not with B57 Status in HIV-1 Elite Controllers. PLoS ONE, 2013, 8, e74855.	2.5	76
71	Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes. Journal of Allergy and Clinical Immunology, 2012, 130, 1368-1374.e2.	2.9	33

72 Definition, Natural History and Heterogeneity of HIV Controllers. , 2012, , 233-252.

4

#	Article	IF	CITATIONS
73	Kidney transplantation in an elite HIV controller: Limited impact of immunosuppressive therapy on viro-immunological status. Journal of Infection, 2012, 64, 630-633.	3.3	4
74	CD4 Dynamics over a 15 Year-Period among HIV Controllers Enrolled in the ANRS French Observatory. PLoS ONE, 2011, 6, e18726.	2.5	52
75	Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood, 2011, 118, 955-964.	1.4	107
76	The role of cytotoxic T cells. Retrovirology, 2010, 7, .	2.0	0
77	Ex vivo T cell–based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses. Nature Protocols, 2010, 5, 1033-1041.	12.0	69
78	Natural Resistance to HIV Infection: Lessons Learned from HIVâ€Exposed Uninfected Individuals. Journal of Infectious Diseases, 2010, 202, S345-S350.	4.0	34
79	Heterogeneity in HIV Suppression by CD8 T Cells from HIV Controllers: Association with Gag-Specific CD8 T Cell Responses. Journal of Immunology, 2009, 182, 7828-7837.	0.8	183
80	Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood, 2009, 113, 6351-6360.	1.4	192
81	The characteristic CD8+ T cell response in HIV controllers: An objective to achieve?. Pathologie Et Biologie, 2008, 56, 251-253.	2.2	1
82	Interfacial pre-transmembrane domains in viral proteins promoting membrane fusion and fission. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 1624-1639.	2.6	61
83	Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36) Tj ETQq1 1 0	.784314 r 2.2	gBŢ /Overloci
84	Ku80 Participates in the Targeting of Retroviral Transgenes to the Chromatin of CHO Cells. Journal of Virology, 2007, 81, 7924-7932.	3.4	15
85	HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6776-6781.	7.1	553
86	A system and methodology for high-content visual screening of individual intact living cells in suspension. , 2007, , .		4
87	HIV controllers: how do they tame the virus?. Trends in Immunology, 2007, 28, 532-540.	6.8	94
88	Persistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks. Retrovirology, 2006, 3, 81.	2.0	18
89	Quantitative real-time analysis of HIV-1 gene expression dynamics in single living primary cells. Biotechnology Journal, 2006, 1, 682-689.	3.5	11
90	The Engagement of Activating Fcl ³ Rs Inhibits Primate Lentivirus Replication in Human Macrophages. Journal of Immunology, 2006, 177, 6291-6300.	0.8	33

#	Article	IF	CITATIONS
91	Pre-transmembrane sequence of Ebola glycoprotein. FEBS Letters, 2003, 533, 47-53.	2.8	39
92	Structural and Functional Roles of HIV-1 gp41 Pretransmembrane Sequence Segmentation. Biophysical Journal, 2003, 85, 3769-3780.	0.5	79
93	The Hydrophobic Internal Region of Bovine Prion Protein Shares Structural and Functional Properties with HIV Type 1 Fusion Peptide. AIDS Research and Human Retroviruses, 2003, 19, 969-978.	1.1	14
94	Sphingomyelin and Cholesterol Promote HIV-1 gp41 Pretransmembrane Sequence Surface Aggregation and Membrane Restructuring. Journal of Biological Chemistry, 2002, 277, 21776-21785.	3.4	119
95	Conformational transitions of membrane-bound HIV-1 fusion peptide. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1564, 57-65.	2.6	56
96	The pre-transmembrane region of the human immunodeficiency virus type-1 glycoprotein: a novel fusogenic sequence. FEBS Letters, 2000, 477, 145-149.	2.8	88
97	Equilibrium and Kinetic Studies of the Solubilization of Phospholipidâ `Cholesterol Bilayers by C12E8. The Influence of the Lipid Phase Structure. Langmuir, 2000, 16, 1960-1968.	3.5	29
98	Sphingolipids (Galactosylceramide and Sulfatide) in Lamellarâ^'Hexagonal Phospholipid Phase Transitions and in Membrane Fusionâ€. Langmuir, 2000, 16, 8958-8963.	3.5	14